SMTI Sanara MedTech Inc.
USHealthcareAs of 2026-07-10 16:00
Why SMTI matters now
Sanara MedTech Inc. (SMTI) is a US stock in Healthcare. The latest InvestLog snapshot shows $23.82 with -0.25% on the session and $218.3M in market capitalization; recent performance reads 1-month -3.08% and YTD -5.70%.
The latest financial table shown here is Q1 2026, with revenue of $27.8M, net income of $459.0K, and EPS of $0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield 1.7%.
The latest indexable market news headline is "INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanara MedTech, Inc. - SMTI" from GuruFocus.
Additional event context on this page matters because analyst consensus is Buy with a median target of $32.00; recent insider activity includes Myers Keith G filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
27.28
P/S
1.88
EV/EBITDA
28.40
DCF Value
$53.91
FCF Yield
1.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
91.2%
Operating Margin
7.9%
Net Margin
-31.2%
ROE
-246.4%
ROA
-48.5%
ROIC
15.1%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $27.8M | $459.0K | $0.05 |
| Q4 2025 | $27.5M | $-1.6M | $-0.20 |
| FY 2025 | $103.1M | $-37.6M | $-4.36 |
| Q3 2025 | $26.3M | $-30.4M | $-3.52 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$32.00
Target (Median)
$32.00
Target Range
$32.00 - $32.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Country
US
Exchange
—
Beta
1.19
Sanara MedTech Inc. is a Fort Worth, Texas-based company established in 2001, dedicated to the development, marketing, and distribution of advanced wound and skin care products. These solutions are provided to a diverse clientele within the United States healthcare sector, including physicians, hospitals, clinics, and post-acute care facilities. The company's extensive product portfolio includes CellerateRX, a line of Surgical Activated Collagen in both powder and gel forms, designed to enhance patient healing across various surgical specialties. Sanara MedTech also offers a suite of Biako's antimicrobial products: a patented Skin and Wound Cleanser engineered to dismantle mature biofilm microbes by disrupting their extracellular polymeric substances, an Antimicrobial Wound Gel effective against both planktonic and biofilm-forming microbes, and an Antimicrobial Skin and Wound Irrigation Solution. Another key offering is HYCOL, a hydrolyzed Type I bovine collagen available as powder and gel, specifically formulated for the management of both full and partial thickness wounds, encompassing conditions such as pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. Additionally, Sanara MedTech is involved in the development of sophisticated biologic devices like FORTIFY TRG, a freeze-dried, multi-layer sheet derived from small intestinal submucosa extracellular matrix, and FORTIFY FLOWABLE extracellular matrix, an innovative wound care solution. The company also provides VIM Amnion Matrix, a single-layer amnion tissue sheet. Initially incorporated as WNDM Medical Inc., the company underwent a name change to Sanara MedTech Inc. in May 2019.